Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

NCT02077933 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Breast Neoplasms
Kidney Neoplasms
Pancreatic Neuroendocine Neoplasms (pNETs)

Interventions

DRUG: alpelisib
DRUG: everolimus
DRUG: exemestane

Sponsor

Novartis Pharmaceuticals